EGFR and neoplasm: Other studies also showed that homo-combinations of two antibodies against EGFR (18–21), HER2 (22–24), or HER3 (25), and hetero-combinations of antibodies against EGFR and HER2 (10–14, 16, 26), or EGFR and HER3 (27, 28) induce anti-tumor activity through accelerated degradation of the targeted receptors, enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and reduction of dimer formation, thus bypassing the resistance to treatment induced by monotherapy.